Published in AIDS on December 06, 2002
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol (2004) 4.12
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33
A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol (2004) 2.33
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol (2003) 1.40
Role of individual's T-cell immunome in controlling HIV-1 progression. Immunology (2014) 1.39
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28
Not all cytokine-producing CD8+ T cells suppress simian immunodeficiency virus replication. J Virol (2006) 1.19
Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS (2008) 1.13
Specific CD8+ T cell responses correlate with control of simian immunodeficiency virus replication in Mauritian cynomolgus macaques. J Virol (2012) 1.06
Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis (2009) 1.02
Breast milk cellular HIV-specific interferon γ responses are associated with protection from peripartum HIV transmission. AIDS (2012) 0.90
Not all tetramer binding CD8+ T cells can produce cytokines and chemokines involved in the effector functions of virus-specific CD8+ T lymphocytes in HIV-1 infected children. J Clin Immunol (2005) 0.90
Accelerated crossing of fitness valleys through division of labor and cheating in asexual populations. Sci Rep (2012) 0.81
Expansion of Simian Immunodeficiency Virus (SIV)-Specific CD8 T Cell Lines from SIV-Naive Mauritian Cynomolgus Macaques for Adoptive Transfer. J Virol (2015) 0.80
Role of avidity and breadth of the CD4 T cell response in progression to AIDS. Proc Biol Sci (2006) 0.79
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines (2008) 0.78
SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251. Virol J (2006) 0.78
Key role of human leukocyte antigen in modulating human immunodeficiency virus progression: An overview of the possible applications. World J Virol (2015) 0.76
Infection of HIV-specific CD4 T helper cells and the clonal composition of the response. J Theor Biol (2012) 0.76
Characterization of Gag and Nef-specific ELISpot-based CTL responses in HIV-1 infected Indian individuals. Med Microbiol Immunol (2008) 0.75
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol (2006) 5.25
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol (2003) 4.15
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol (2004) 3.99
Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS (2006) 3.82
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (2008) 3.44
HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr (2007) 3.38
Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis (2009) 3.28
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol (2005) 3.18
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer (2004) 2.98
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis (2010) 2.90
Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol (2006) 2.82
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
HIV and coronary heart disease: time for a better understanding. J Am Coll Cardiol (2013) 2.78
Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS (2008) 2.74
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol (2010) 2.64
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat (2010) 2.50
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Accelerated immune senescence and HIV-1 infection. Exp Gerontol (2007) 2.41
Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2004) 2.14
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11
Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med (2004) 2.08
The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS (2014) 2.04
Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis (2005) 2.03
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis (2006) 2.02
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol (2009) 1.98
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS (2003) 1.97
Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93
HIV infection in older patients in the HAART era. J Antimicrob Chemother (2005) 1.90
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res (2008) 1.89
PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS (2007) 1.88
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther (2007) 1.83
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med (2012) 1.77
Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol (2005) 1.77
Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS (2009) 1.74
Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr (2007) 1.68
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (2004) 1.67
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS (2010) 1.65
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS (2003) 1.64
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63